RIPK1 and neoplasm: For ICB resistance, interferon-γ receptor (IFNGR) signalling drives RIPK1 overexpression in tumour cells; genetic ablation of RIPK1 enhances ICB sensitivity in murine melanoma and breast cancer models.92